Market Place
Sourcing Support
Kronos Bio Highlights p300 KAT Inhibitors at ACR
14 Nov 2024 //
GLOBENEWSWIRE
Kronos Bio Reports Q3 2024 Results & Strategic Plans
13 Nov 2024 //
GLOBENEWSWIRE
Kronos Bio Presents p300 KAT Data in Myeloma at ASH 2024
05 Nov 2024 //
GLOBENEWSWIRE
Kronos Bio Highlights p300 KAT Inhibition at EORTC-NCI-AACR
23 Oct 2024 //
GLOBENEWSWIRE
Kronos Bio To Present Data On p300 KAT Inhibition EORTC-NCI Symposium
09 Oct 2024 //
GLOBENEWSWIRE
Kronos Bio Selects Autoimmune Candidate For Sjögren`s Disease
07 Oct 2024 //
GLOBENEWSWIRE
Kronos Bio To Present At ACR Convergence 2024
25 Sep 2024 //
GLOBENEWSWIRE
Kronos Bio Presents Istisociclib Data At AACR Ovarian Symposium
23 Sep 2024 //
GLOBENEWSWIRE
Kronos Bio to Participate in September Medical and Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
08 Aug 2024 //
GLOBENEWSWIRE
Kronos Bio Doses First Patient With KB-0742 In Ovarian Cancer Cohort
23 Jul 2024 //
GLOBENEWSWIRE
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
22 May 2024 //
GLOBENEWSWIRE
Kronos Bio Appoints Knobelman As COO, CFO
21 May 2024 //
GLOBENEWSWIRE
Kronos Bio Reports First-Quarter 2024 Financial Results
09 May 2024 //
GLOBENEWSWIRE
Kronos Bio to Present KB-0742 Trial Update at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
Kronos Bio Reports Recent Business Progress and Q4 and FY23 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development
07 Mar 2024 //
GLOBENEWSWIRE
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
05 Mar 2024 //
GLOBENEWSWIRE
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
27 Feb 2024 //
GLOBENEWSWIRE
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
25 Jan 2024 //
GLOBENEWSWIRE
Kronos calls time on CMO, CSO roles as part of C-suite shakeup
25 Jan 2024 //
FIERCE BIOTECH
Kronos discontinues mid-stage AML trial after poor response
19 Dec 2023 //
FIERCE BIOTECH
Kronos Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
18 Dec 2023 //
GLOBENEWSWIRE
Kronos Announces Participation in H.C. 4th Annual Precision Oncology Conference
04 Dec 2023 //
GLOBENEWSWIRE
Kronos Bio Announces Participation in 35th Annual Piper Sandler Conference
27 Nov 2023 //
GLOBENEWSWIRE
Kronos Bio Reports Business Progress and Third-Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Kronos cuts 19% of staff to make way for solid tumor drug
03 Nov 2023 //
FIERCE BIOTECH
Kronos Bio Presents Positive Preliminary Data from the Phase 1 of KB-0742 Study
02 Nov 2023 //
GLOBENEWSWIRE
Kronos Bio Announces Plan to Optimize Resource Allocation
02 Nov 2023 //
GLOBENEWSWIRE
Kronos Bio To Present Positive Data from Phase 1 of KB-0742 Study
27 Oct 2023 //
GLOBENEWSWIRE
Kronos Bio Presents Positive Preliminary Data from Phase 1 of KB-0742 Study
13 Oct 2023 //
GLOBENEWSWIRE
Kronos Bio To Present Interim Data from Phase 1 of Ongoing KB-0742 Study
04 Oct 2023 //
GLOBENEWSWIRE
Kronos Bio Announces Departure of CFO and Head of Corporate Development
17 Aug 2023 //
GLOBENEWSWIRE
Kronos Bio Reports Second-Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President
06 Jun 2023 //
GLOBENEWSWIRE
Kronos Bio Announces Participation in Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
Kronos Bio Reports Recent Business Progress and 1Q 2023 Financial Results
10 May 2023 //
GLOBENEWSWIRE
Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors
24 Apr 2023 //
GLOBENEWSWIRE
Kronos Bio Announces Changes to Board of Directors
11 Apr 2023 //
GLOBENEWSWIRE
Kronos Bio Reports Fourth-Quarter and Full-Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
28 Feb 2023 //
GLOBENEWSWIRE
Kronos Bio Announces Collaboration with Genentech to Advance Novel Therapies
09 Jan 2023 //
GLOBENEWSWIRE
Kronos Presents Data Supporting Anti-Leukemic Activity of Lanraplenib with AML
11 Dec 2022 //
GLOBENEWSWIRE
Kronos Bio Announces Selection of Recommended Ph2 Dose for Oral CDK9, KB-0742l
07 Dec 2022 //
GLOBENEWSWIRE
Kronos Bio Announces Participation in Upcoming Investor Conferences
22 Nov 2022 //
GLOBENEWSWIRE
Kronos blames enrollment troubles for ending phase 3 AML program
10 Nov 2022 //
FIERCEBIOTECH
Kronos Bio Reports Recent Business Progress and 3Q 2022 Financial Results
08 Nov 2022 //
GLOBENEWSWIRE
Kronos Bio Announces Prioritization of Clinical Portfolio toFocus on Lanraplenib
08 Nov 2022 //
BIOSPACE
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor
12 Oct 2022 //
GLOBENEWSWIRE
Kronos Bio Announces Participation in H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Kronos Begins Dosing in PIb/II Trial of Lanraplenib with Gilteritinib
22 Aug 2022 //
GLOBENEWSWIRE
Kronos Bio and Invivoscribe Partner for Use with Entospletinib
16 Aug 2022 //
PRNEWSWIRE
Kronos Bio Reports Second-Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Kronos Bio to Advance novel SYK Inhibitors Entospletinib and Lanraplenib
09 Jun 2022 //
GLOBENEWSWIRE
Kronos Bio Announces Participation in Upcoming Investor Conferences
01 Jun 2022 //
GLOBENEWSWIRE
Kronos Bio`s SYK Inhibitors Entospletinib and Lanraplenib at EHA 2022
12 May 2022 //
GLOBENEWSWIRE
Kronos Bio Presents Preclinical Data on KB-0742 in Tumors at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Kronos Bio`s KB-0742 to be Featured in4 PC Poster Presentations at AACR
08 Mar 2022 //
GLOBENEWSWIRE
Kronos Bio Reports Q4 and Full-Year 2021 Financial Results
24 Feb 2022 //
GLOBENEWSWIRE
Kronos Bio Announces Positive Data from Ongoing Ph 1/2 Trial KB-0742
29 Nov 2021 //
GLOBENEWSWIRE
